Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Operations (2018 - 2025)

UroGen Pharma's Cash from Operations history spans 8 years, with the latest figure at 38325000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 181.41% year-over-year to 38325000.0; the TTM value through Dec 2025 reached 162444000.0, down 67.87%, while the annual FY2025 figure was 162444000.0, 67.87% down from the prior year.
  • Cash from Operations reached 38325000.0 in Q4 2025 per URGN's latest filing, up from 42270000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 12996000.0 in Q4 2023 to a low of 42270000.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 25401850.0, with a median of 23872000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: skyrocketed 40.25% in 2023, then plummeted 181.41% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 20070000.0 in 2021, then fell by 8.38% to 21752000.0 in 2022, then surged by 40.25% to 12996000.0 in 2023, then decreased by 4.79% to 13619000.0 in 2024, then tumbled by 181.41% to 38325000.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Cash from Operations are 38325000.0 (Q4 2025), 42270000.0 (Q3 2025), and 39825000.0 (Q2 2025).